BioSpace News Archive

EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that based on feedback from a meeting with the U.S.

Microbix Biosystems Inc. announces that it has completed two processes to make its common shares available for U.S. investors to buy and sell; the listing of its common shares on the OTCQB platform under the ticker symbol MBXBF, and approval for electronic clearance and settlements of trades by way of DTC Eligibility.

Cardiovascular Systems, Inc. will host a live webcast of its fiscal 2020 fourth-quarter conference call on Tuesday, August 4, 2020, at 3:30 p.m. CT.

QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status

JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China , Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition to royalties on sales SAN FRANCISCO and TAIPEI, Taiwan, July 14, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) technology platform and JW Therapeutics, a biotechnology company focusing on the

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold a conference call for investors on Wednesday, July 29, 2020, at 5:00 p.m. Eastern Time. During the conference call, management will review highlights from the Company’s second quarter 2020 financial results, which will be announced via press release after the close of market trading. The conference call can

The Lupus Research Alliance (LRA) is pleased to announce the first recipients of the inaugural LRA-BMS Accelerator Award*, a collaborative project with sponsoring partner Bristol Myers Squibb. The Award provides a collective total of $3,000,000 to support nine cutting-edge lupus research projects over two years that focus on understanding t

Sanofi Canada is pleased to announce a positive recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for DUPIXENT® (dupilumab) for Quebec residents aged 12 to 17 years with moderate-to-severe atopic dermatitis whose disease is not adequately managed with current therapy and when specific conditions are met

In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis